诊断投资与疾病负担：监管和支付政策如何促进诊断创新

Regulatory and payment policies could facilitate investment and innovation in diagnostics Kathryn A. Phillips1,2, Danea M. Horn1,2, Robert M. Califf3 S creening and testing for disease using “diagnostics” (see the box) is increasingly essential across global health care sys- tems to identify and target individuals who will most benefit from health care interventions and to address unmet disease burden. However, access to diagnostics is uneven and often inadequate, particularly in lower- and middle-income countries, with an estimated 47% of the world’s population having limited or no access to diagnostics (1). Despite these needs, diagnostics historically have re- ceived lower investment, insurance coverage, and payment rates than drugs, creating barriers to innovation (2). …